ImmunoMet Therapeutics Employee Directory

ImmunoMet Therapeutics corporate office is located in 2450 Holcombe Blvd, Houston, Texas, 77021, United States and has 11-50 employees.

ImmunoMet Therapeutics Global Presence

globalPresence illustration
North America1-10

ImmunoMet Therapeutics CEO

DW
United States flag for contact location.
Dean WelschChief Executive Officer
Flame icon indicating likelihood to engage via phone.PhonePhoneFlame icon indicating likelihood to engage via email.EmailEmail
See Profile

Key Employees of ImmunoMet Therapeutics

  • LM
    United States flag for contact location.
    Laura Mei

    Senior VP, Clinical Operations

    PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail

Index of contact profiles from ImmunoMet Therapeutics

Hundreds of professionals searching for ImmunoMet Therapeutics have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
12

Former Employees at ImmunoMet Therapeutics

Explore people who held key positions, contributed to ImmunoMet Therapeutics's success, and advanced their careers.

People from Similar Companies in the Manufacturing Industry Located in Texas, United States

Frequently Asked Questions Regarding ImmunoMet Therapeutics Employees

How many employees does ImmunoMet Therapeutics have?
ImmunoMet Therapeutics has 11-50 employees
Who is the CEO of ImmunoMet Therapeutics?
ImmunoMet Therapeutics’s CEO is Dean Welsch
Who are ImmunoMet Therapeutics key employees?
Some of ImmunoMet Therapeutics key employees are Laura Mei
Where is ImmunoMet Therapeutics located?
ImmunoMet Therapeutics’s headquarters are located at 2450 Holcombe Blvd, Houston, Texas, 77021, United States
How do I contact ImmunoMet Therapeutics?
ImmunoMet Therapeutics Contact Info: Phone number: (346) 772-0318 Website: www.immunomet.com
What does ImmunoMet Therapeutics do?

ImmunoMet Therapeutics is a clinical-stage oncology company focused on developing novel cancer drugs by targeting metabolic dependencies in resistant tumors. Their lead asset, lixumistat (IM156), is a best-in-class OxPhos inhibitor that aims to improve treatment options for patients with advanced pancreatic cancer. The company has shown promising e... arly results in clinical trials, particularly at MD Anderson Cancer Center, with a notable response rate in patients. ImmunoMet Therapeutics seeks to engage with investors and partners to further advance their innovative therapies in the oncology market.Read More

Is ImmunoMet Therapeutics a public company?
ImmunoMet Therapeutics is private company therefore does not currently have an official ticker symbol
See more information about ImmunoMet Therapeutics Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.